Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck and Co Inc | 1,599 |
| 2 | Takeda Pharmaceutical Co Ltd | 1,109 |
| 3 | Ono Pharmaceutical Co Ltd | 1,009 |
| 4 | Sanofi SA | 950 |
| 5 | AstraZeneca PLC | 782 |
| 6 | C.H. Boehringer Sohn AG and Co KG | 463 |
| 7 | Organon and Co | 435 |
| 8 | AbbVie Inc | 425 |
| 9 | Roche Holding AG | 413 |
| 10 | Gilead Sciences Inc | 389 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | C07D | Heterocyclic compounds | 22,805 |
| 2 | A61P | Therapeutic activity (drug indications) | 22,314 |
| 3 | A61K | Medicinal preparations | 14,241 |
| 4 | C07C | Acyclic and carbocyclic compounds | 2,995 |
| 5 | C07F | Organometallic compounds | 1,982 |
| 6 | C07K | Peptides | 1,201 |
| 7 | Y02A | Climate change adaptation | 915 |
| 8 | C07B | General methods of organic chemistry | 881 |
| 9 | A01N | Preservation of bodies; biocides; pest repellents | 853 |
| 10 | Y02P | Climate change mitigation: production | 711 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Tetrahydropyridine oxime compounds | 1990 | Pfizer Inc | 72 |
| O-substituted tetrahydropyridine oxime cholinergic agents | 1987 | Pfizer Inc | 72 |
| 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | 2008 | AstraZeneca PLC | 66 |
| Thieno tetrahydropyridines useful as class III antiarrhythmic agents | 1994 | Johnson and Johnson | 64 |
| 2 -BENZIMIDAZOLYL- 6 -MORPHOLINO-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | 2008 | AstraZeneca PLC | 57 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 535 |
| 2017 | 508 |
| 2018 | 526 |
| 2019 | 465 |
| 2020 | 493 |
| 2021 | 466 |
| 2022 | 256 |
| 2023 | 146 |
| 2024 | 392 |
| 2025 | 168 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | James E. Foley | Novartis (United States) | 39 |
| 2 | Kenner C. Rice | National Institute on Drug Abuse | 38 |
| 3 | Anja Schweizer | Novartis (Switzerland) | 32 |
| 4 | Kazuaki Chayama | Hiroshima University | 29 |
| 5 | Vern L. Schramm | Albert Einstein College of Medicine | 25 |
| 6 | Fiona McPhee | Bristol-Myers Squibb (United States) | 17 |
| 7 | Bo Åhrén | Lund University | 16 |
| 8 | Klaus Tatsch | Ludwig-Maximilians-Universität München | 16 |
| 9 | Terry J. Opgenorth | Abbott Fund | 16 |
| 10 | Eric Hughes | Bristol-Myers Squibb (United States) | 14 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields | 2009 | 7704 | Protein Structure and Dynamics |
| Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. | 1994 | 2223 | Nitric Oxide and Endothelin Effects |
| Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele | 2019 | 2176 | Cystic Fibrosis Research Advances |
| Therapeutic siRNA: state of the art | 2020 | 1554 | MicroRNA in disease regulation |
| Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. | 1992 | 1524 | Immune Response and Inflammation |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of pyrrolidines?
Which companies have the most patents related to pyrrolidines?
What are the primary patent classification areas for pyrrolidine compounds?
How has publication activity for pyrrolidines changed in recent years?
What is the total scope of research and patent activity for pyrrolidines?